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Abstract
Background: The concerns about the development of adverse events (AEs) in elderly RA patients as a result of
age-related changes in drug metabolism and the presence of comorbid illnesses are emphasizing due to increasing
prevalence of rheumatoid arthritis (RA) in old age. However, they tend to be inadequately represented in RA clinical
trials because of the exclusion criteria that are commonly applied. The tolerability and safety of TNF inhibitors in
elderly patients have not been also evaluated in clinical practice. This study aimed to evaluate the retention rate
and safety of TNF inhibitors (TNFI) in elderly RA patients.
Methods: Total 429 RA patients (838 person-years [PYs]) treated with TNFI from a retrospective biologic DMARDs
registry. Patients were divided into an elderly (age ≥60 years) and a younger group (<60 years). The drug retention
rates of both groups were compared using Kaplan-Meier curves. Potential predictors of TNFI discontinuation in the
elderly were examined using Cox regression analysis. The incidence rate (IR) of serious adverse events (SAEs) in the
elderly group was compared to that of the young group.
Results: Of the patients, 24.9 % (n = 107, 212 PYs) were in the elderly group. Regarding the retention rates of TNFI
in 3 years, there was no significant difference between the elderly and younger group (p = 0.33). The major cause of
discontinuation in elderly patients was AE (34.3 %), whereas that was drug ineffectiveness (41.7 %) in younger
patients. Age (HR 1.09, CI 1.02-1.16) was a predictor of discontinuation, while the presence of comorbidity
(HR 0.37, CI 0.15-0.91) had a protective effect against drug discontinuation in the elderly. The IR of SAEs in
the elderly (6.13/100 PYs) was higher than in the younger group (5.11/100 PYs).
Conclusions: The retention rate of TNFI in the elderly was comparable with that in younger patients. The
major cause of discontinuation in the elderly patients was AEs, while it was drug ineffectiveness in younger
patients. The IR of SAEs in the elderly was higher than in the younger patients.
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Background
Rheumatoid arthritis (RA) is a chronic inflammatory
disease that causes joint destruction and disability. The
incidence of RA increases with age, peaking between the
fourth and sixth decades [1]. Elderly patients diagnosed
after the age of 60 comprise 15–33 % of RA patients [2, 3].
A Finnish observational study suggested that the mean age
at diagnosis had increased from 50.2 years old to 57.8 years
old over 15 years [4]. Along with increasing life expectancy
in the industrialized world, these observations suggest that
the number of elderly RA patients will increase [5, 6].
However, elderly patients may be less likely to receive
tumor necrosis factor (TNF) inhibitors due to their
greater likelihood of comorbid conditions than younger
patients, and there are often contraindications to treat-
ment with biologic agents [7, 8]. In addition, there have
been concerns that elderly patients have a higher risk of
adverse events (AEs) including infection [9]. These fac-
tors complicate disease treatment and necessitate careful
patient management. Although the treatment goals for
elderly RA patients are not different from those of* Correspondence: scbae@hanyang.ac.kr1Department of Rheumatology, Hanyang University Hospital for Rheumatic
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younger individuals, the potential risk of developing
drug-related AEs in elderly patients is increasing [7].
Previous clinical trials suggest that disease-modifying
anti-rheumatic drugs (DMARDs) and TNF inhibitors are
efficacious and well tolerated in elderly patients [10, 11].
However, elderly patients tend to be inadequately repre-
sented in RA clinical trials due to the exclusion criteria
that are commonly applied [12]. Therefore, patients with
RA in clinical practice might differ from patients
selected for inclusion in clinical trials. To complement
evidence obtained from clinical trials, a long-term obser-
vational study that evaluates effectiveness and safety in
clinical practice is needed.
This study aimed to examine the retention and safety of
TNF inhibitors in elderly patients with RA compared to a




A retrospective registry of Korean patients with RA
(REtrospective study for Safety and Effectiveness of
Anti-RA treatment with biologiCs, RESEARCh) was
established to evaluate the safety and effectiveness of
biologic DMARDs [13]. Patients who meet the 1987
American College of Rheumatology criteria for RA who
had ever been given biologic DMARDs from December
2000 to June 2011 were identified from the medical
records of Hanyang University Hospital for Rheumatic
Diseases and enrolled in the RESEARCh database.
Comprehensive chart reviews for all patients were
undertaken by well-trained health professionals from
November 2009 to August 2011. Demography, disease
activity, comorbidities: cardiovascular disease, pulmon-
ary disease, previous history of pulmonary tuberculosis,
gastrointestinal disease, hepatobiliary disease, diabetes
mellitus, malignancy, hypertension, thyroid disease, and
renal disease, treatments, and laboratory data at the first
dose of biologic DMARDs were recorded. Comorbidities
were assessed at the time of starting biologic DMARDs
and were classified by organ system.
Patients and follow-up
A total of 429 RA patients (838 person-years [PYs]) treated
with TNF inhibitors were included in this study. Patients
were divided into two groups: elderly (age ≥60 years) and
younger (age <60 years). The mean observational period
was 23.4 ± 23.9 months, with 23.8 ± 25.8 months in the
elderly group and 23.3 ± 23.2 months in the younger
group.
Drug retention and discontinuation
The observation period for this study started at the first
dose of TNF inhibitors. Observation of each patient was
stopped either at discontinuation of TNF inhibitors,
switching to other biologic DMARDs, death, loss to
follow-up, or enrollment in clinical trials, whichever
came first. Treatment discontinuation was defined as
stopping TNF inhibitor administration for more than
90 days. Reasons for discontinuing TNF inhibitors were
retrieved from medical records and classified into
adverse events (AEs), ineffectiveness, good effectiveness,
patient need, economic reasons, or miscellaneous.
Serious adverse events (SAEs)
SAEs, including serious infection (SI), were defined
based on a report by the International Conference on
Harmonization [14]. Bacterial infections that required
intravenous administration of antibiotics, as well as op-
portunistic infections, were also regarded as SAEs. SAEs
were classified using the System Organ Class (SOC) of
the medical dictionary for regulatory activities (MedDRA
version 11.1). SAEs were attributed to TNF inhibitors
when they developed during treatment with these
biologics, and no risk window was applied.
Statistical analysis
A comparison of demographic and clinical features be-
tween elderly and younger groups was performed using
the chi-square test for categorical variables and the
Student t-test for continuous variables. The drug reten-
tion rate of the elderly group was estimated using
Kaplan-Meier analysis, and it was compared with that of
the younger group using a log-rank test. Potential
predictors of TNF inhibitor discontinuation were also
examined using Cox regression analyses. The incidence
rate (IR) of SAEs was evaluated in each group and the
incidence rate ratio (IRR) of the elderly group with 95 %
confidence intervals (CI) was compared to that of the
younger group.
These statistical analyses were conducted using SAS 9.2
(SAS Institute, Cary NC). All p values were two-tailed,
and p < 0.05 was considered statistically significant.
Results
Baseline characteristics of elderly RA patients who started
TNF inhibitors
Of 429 RA patients treated with TNF inhibitors, 24.9 % (n
= 107, 212 PYs) were included in the elderly group and
322 (626 PYs) were included in the younger group. The
elderly group had more males than the young group
(22.4 % vs. 11.2 %, p = 0.01). The elderly group tended to
use methotrexate (MTX) at a lower dosage than the
younger group (13.6 ± 3.5 mg/week vs. 14.2 ± 3.6 mg/
week, p = 0.20) and glucocorticoids at a higher dosage
(prednisolone (PSL)-equivalent dose, 6.3 ± 4.4 mg/day vs.
6.0 ± 4.1 mg/day, p = 0.66), but there was no significant
difference. The mean number of previous non-biologic
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DMARDs was higher as 4.4 ± 1.7 in the elderly group than
in the younger group (3.9 ± 1.5, p = 0.01).
The prevalence of comorbidities was significantly
different between the two groups. The elderly group had
more comorbid conditions such as cardiovascular
disease (7.5 % for the elderly group vs. 1.2 % for the
younger group), pulmonary disease (15.9 % for the eld-
erly group vs. 1.9 % for the younger group), including
interstitial lung disease, asthma, and chronic obstructive
pulmonary disease. Diabetes mellitus (18.7 % for the
elderly group vs. 6.5 % for the younger group), and
hypertension (46.7 % for the elderly group vs. 14.0 % for
the younger group, p < 0.001),were also more frequent in
the elderly group. Mean Disease Activity Score (DAS) was
calculated based on three variables, including 28- swollen
and tender joints count and erythrocyte sedimentation
rate (ESR). Mean DAS at start of biologic DMARDs did
not differ between the two groups (Table 1).
Drug retention rate of TNF inhibitor in elderly patients
In the analysis of TNF inhibitor retention rates, there
was no significant difference over three years between
the elderly and young groups (59.0 % in elderly group,
50.8 % in younger group, p = 0.33 by log-rank test)
(Fig. 1). The median (interquartile range [IQR]) treat-
ment period for each group was 2.0 (95 % CI 0.3–2.6)
years for the elderly group and 1.9 (95 % CI 0.5–2.8)
years for the younger group. The numbers of patients
who discontinued TNF inhibitors for any reason during
the observation period were 35 (32.7 %) for the elderly
group and 132 (41.0 %) for the younger group (p = 0.16
by chi-square test). There was a difference in the
Table 1 Comparison of demographic and clinical characteristics in elderly and younger patients treated with TNF inhibitors
Total (n = 429) Elderly patients (n = 107) Younger patients (n = 322) p-value
Age, year 49.5 ± 13.6 66.1 ± 5.4 44.0 ± 10.6 <0.01
Sex, male 60 (14.0) 24 (22.4) 36 (11.2) 0.01
Disease duration, years 8.6 ± 6.8 10.0 ± 7.9 8.2 ± 6.4 0.03
First use of TNF inhibitor 329 (76.7) 83 (77.6) 246 (76.4) 0.91
Number of previous non-biologic DMARDs used 4.1 ± 1.5 4.4 ± 1.7 3.9 ± 1.5 0.01
Concomitant MTX use 311 (72.5) 79 (73.8) 232 (72.1) 0.75
Concomitant MTX dosage, mg/week 14.0 ± 3.8 13.6 ± 3.5 14.2 ± 3.6 0.20
Concomitant glucocorticoid use 331 (77.2) 83 (77.6) 248 (77.0) 1.00
Concomitant glucocorticoid dosage, mg/day 6.0 ± 4.1 6.5 ± 5.8 5.8 ± 3.4 0.34
RF positivity 327 (76.2) 84 (78.5) 243 (75.5) 0.59
DAS28-ESR* 6.0 ± 0.9 6.0 ± 0.8 6.0 ± 0.9 0.46
Comorbid conditions
Cardiovascular disease 12 (2.8) 8 (7.5) 4 (1.2) <0.01
Pulmonary diseasea 23 (5.4) 17 (15.9) 6 (1.9) <0.01
Previous history of pulmonary tuberculosis 41 (9.6) 14 (13.1) 27 (8.4) 0.21
Gastrointestinal disease 138 (32.2) 41 (38.3) 97 (30.1) 0.15
Hepatobiliary diseaseb 46 (10.7) 13 (12.2) 33 (10.3) 0.71
Diabetes mellitus 41 (9.6) 20 (18.7) 21 (6.5) <0.01
Malignancy 18 (4.2) 7 (6.5) 11 (3.4) 0.17
Hypertension 95 (22.1) 50 (46.7) 45 (14.0) <0.01
Thyroid disease 26 (6.1) 7 (6.5) 19 (5.9) 0.99
Renal diseasec 10 (2.3) 1 (0.9) 9 (2.8) 0.46
Biologic agents
Etanercept 264 (61.5) 72 (67.3) 192 (59.6) 0.34
Adalimumab 113 (26.3) 25 (23.4) 88 (27.3)
Infliximab 52 (12.1) 10 (9.4) 42 (13.0)
aPulmonary disease: interstitial lung disease, asthma, or chronic obstructive pulmonary disease, bHepatobiliary disease: hepatitis B, hepatitis C, fatty liver, liver
cirrhosis; cRenal disease: Modification of Diet in Renal Disease (MDRD) GFR < 15
TNF tumor necrosis factor, RA rheumatoid arthritis, MTX methotrexate, DMARD disease modifying anti-rheumatic drug, DAS28 disease activity score with 28 joint
assessment, ESR erythrocyte sedimentation rate
*DAS28ESR(3) is the disease activity score calculated from three variables including tender joint count, swollen joint count, and ESR
Bold means statistical significant at the p < 0.05
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frequency of discontinuation by reason: development of
AE (34.3 %) was the most common reason in the elderly
group, while ineffectiveness (41.7 %) was the most com-
mon reason in the younger group, but this difference
was not statistically significant (Table 2).
Risk factors for TNF inhibitor discontinuation in
the elderly group were different from those in the
younger group. A predictor of TNF inhibitor discon-
tinuation in the elderly group was increasing age
(hazard ratio [HR] 1.09, CI 1.02 - 1.16), while the
presence of a comorbidity (HR 0.37, CI 0.15-0.91)
was a protective factor. For the younger group, first
use of a TNF inhibitor (vs. switcher, HR 1.75, CI
1.06-2.94) was a predictor for discontinuation, while
longer disease duration (HR 0.97, CI 0.94 – 0.997)
had a protective effect against discontinuation of TNF
inhibitors (Table 3).
Safety of TNF inhibitors in elderly RA patients
The types and occurrence of SAEs were evaluated.
Among 0107 elderly RA patients with 212 PYs, 13 SAEs
were reported during the observation period, while 32
SAEs were found in 322 younger patients with 626 PYs.
Infection, injury and malignancy were common events
in elderly RA patients (five cases, two cases and two
cases, respectively), while infection and malignancy were
the most common event in younger patients (15 and six
cases). The incidence rate of SAEs was slightly higher in
the elderly group (6.13/100 PYs) than in the younger
group (5.11/100 PYs). The IRs of injury (0.94/100 PYs)
and respiratory disorder (0.47/100 PYs) for the elderly
group were higher than those of the younger group (0.48/
100 PYs and 0.16/100 PYs, respectively). The crude IRR
comparing elderly RA patients with young RA patients for
all SAEs was 1.20 (95 % CI, 0.63-2.29). The IRRs for injury
Fig. 1 Persistence rate of TNF inhibitors. a Persistence rate of TNF inhibitors in total patients. b Comparison of TNF inhibitor persistence rate between
elderly patients and younger patients
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and respiratory disorder were 1.97 (95 % CI, 0.33-11.78)
and 2.95 (95 % CI, 0.18-47.21), respectively, (Table 4).
Discussion
This study demonstrates that the retention rate of
TNF inhibitors in elderly RA patients is comparable
to that of younger patients in clinical practice. How-
ever, major causes of drug discontinuation differed,
with development of AEs in elderly patients and inef-
fectiveness in younger patients. The predictors of
TNF inhibitor discontinuation also differed. Predictors
for discontinuation were glucocorticoid use and older
age in elderly RA patients while first use of TNF
inhibitor and short disease duration were predictors
in younger patients. The incidence of overall SAEs in
elderly RA patients was higher than that in younger
patients, with a IRR of 1.22.
Retention rates of 71.7 % after 1 year, 60.4 % after
2 years, and 52.7 % after 3 years were observed in RA
patients. Elderly patients had a similar TNF inhibitor re-
tention rate at 3 years compared with younger patients,
with retention rates of 75.2 % for one year, 66.1 % for
two years, and 59.0 % for three years, respectively. Previ-
ous observational studies reported the good effectiveness
of TNF inhibitors in elderly RA patients using out-
comes of disease activity changes or functional disability
[6, 15–18]. A Dutch registry reported that elderly patients
with RA exhibit reduced response to treatment with TNF
inhibitors [15]. We cannot directly compare our results
with those of previous reports because we did not
Table 3 Risk factors for TNF inhibitor discontinuation in RA patients
Total RA Elderly patients Young RA
Adjusted HR (95 % CI) p Adjusted HR (95 % CI) p Adjusted HR (95 % CI) p
Age at start of biologics 1.00 (0.99 – 1.02) 0.66 1.09 (1.02 – 1.16) <0.01 1.00 (0.99 – 1.02) 0.64
Sex, female 1.06 (0.65 – 1.74) 0.81 1.81 (0.64 – 5.12) 0.27 0.84 (0.47 – 1.49) 0.55
Switcher vs. first user 0.55 (0.35 – 0.86) <0.01 0.43 (0.16 – 1.22) 0.11 0.57 (0.34 – 0.94) 0.03
Disease duration, per year 0.97 (0.95 – 0.997) 0.03 0.96 (0.91 – 1.00) 0.05 0.97 (0.94 – 0.997) 0.03
Biologics
Etanercept 1.00 1.00 1.00
Infliximab 1.44 (0.92 – 2.27) 0.11 0.43 (0.10 – 1.97) 0.28 1.81 (1.11 – 2.95) 0.02
Adalimumab 0.88 (0.59 – 1.32) 0.54 0.72 (0.30 – 1.74) 0.46 0.86 (0.54 – 1.37) 0.53
Concomitant use of methotrexate 0.72 (0.51 – 1.01) 0.06 0.44 (0.21 – 0.91) 0.03 0.91 (0.62 – 1.35) 0.64
Concomitant glucocorticoid dosage
<5 mg/day 1.00 1.00 1.00
≥5 mg/day 1.05 (0.76 – 1.46) 0.75 1.18 (0.53 – 2.62) 0.68 0.97 (0.67 – 1.41) 0.89
Comorbiditya 0.91 (0.64 – 1.29) 0.59 0.37 (0.15 – 0.91) 0.03 1.04 (0.71 – 1.52) 0.83
TNF tumor necrosis factor, HR hazard ratio, CI confidence interval, RA rheumatoid arthritis
aComorbidity: the presence of a comorbid condition
Bold means statistical significant at the p < 0.05
Table 2 Reasons for discontinuation of TNF inhibitors, N (%)
Total (n = 429) Elderly patients (n = 107) Younger patients (n = 322) p value
Number of discontinuations 167 (38.9) 35 (32.7) 132 (41.0) 0.16
Reason for discontinuation 0.43
Adverse effect 44 (26.4) 12 (34.3) 32 (24.2)
Ineffectiveness 64 (38.3) 9 (25.7) 55 (41.7)
Patient need 37 (22.2) 9 (25.7) 28 (21.2)
Good effectiveness 7 (4.2) 2 (5.7) 5 (3.8)
Economic problem 3 (1.8) 1 (2.9) 2 (1.5)
Operation or hospitalization 4 (2.4) 1 (2.9) 3 (2.3)
Othera 3 (1.8) 1 (2.9) 2 (1.5)
Unknown 5 (3.0) - 5 (3.8)
aOther reasons include mobility impaired, preparation for pregnancy, and dental treatment
Bold means statistical significant at the p < 0.05
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estimate response rates based on ACR 20 or DAS28. How-
ever, our results showed similar retention rates for TNF in-
hibitors at three years in the elderly group and younger
group despite a higher rate of SAEs in elderly patients.
The most common cause of discontinuation differed
for elderly and younger groups. AE was the most com-
mon cause of discontinuation in the elderly patients,
while ineffectiveness was the most common cause in the
younger group. This tendency was also demonstrated in
an Italian registry in which discontinuation due to AEs
(21.8 %) was more frequent than discontinuation due to
ineffectiveness (17.4 %) in elderly patients [16].
The presence of comorbidity showed a protective
effect for discontinuation of TNF inhibitors in the
elderly group. This result was somewhat different from
that of a previous study reporting that increased age was
associated with a greater number of comorbidities and
suggesting that comorbidities were associated with
poorer response outcomes for disease activity or func-
tional disability [19]. Since comorbidity affects not only
treatment outcomes but also treatment decisions [20], it
might be associated with persistence of TNF inhibitors
in a different way. In some previous studies, greater co-
morbidity was associated with greater discontinuation
rate of TNF inhibitors [21–23], whereas other studies
noted a positive influence of comorbidities on the drug
persistence [24, 25]. RA patients with biologic DMARDs
have been shown to have high levels of baseline comor-
bidity [26]. However, TNF inhibitors have restricted
applications in some comorbid conditions, such as con-
gestive heart failure, infection, and malignancy. There-
fore, in accordance with our study, comorbid conditions
in RA patients that are treated with TNF inhibitors in clin-
ical practice may not lead to drug discontinuation and
contribute to maintain TNF inhibitor treatment because
these injectable agents reduce the number and/or dose of
medications, such as glucocorticoid and immunosuppres-
sive agents. In the younger group, first use and short dis-
ease duration were related to discontinuation of TNF
inhibitors. This may indicate that intensive drug switching
is more common in younger patients than elderly patients,
since they are more socially active.
The IR of overall SAE in elderly patients was numeric-
ally higher than in the young patients (IRR 1.20, 95 % CI
0.63-2.29). Among various SAEs, the incidence of injury
and respiratory disorder in elderly patients was higher
than those in young patients. Previous observational
studies have reported that elderly patients were more
susceptible to infection [16, 27–30]. These results may be
from more risk factors for infection in elderly RA patients,
including higher prevalence of comorbidity, elevated
markers of disease activity, and history of previous infec-
tion [31]. The malignancy risk in elderly patients receiving
TNF inhibitors is controversial. In a Swiss registry, malig-
nancy risk was higher in elderly users of TNF inhibitors
[18], but other observational studies showed that there
was no increase in the risk of malignancy in elderly pa-
tients treated with TNF inhibitors [31, 32]. In subgroup
analysis for elderly patients more than 65 years old of our
results, infection and malignancy risks were higher in the
elderly group than in the younger group, but the differ-
ence was not statistically significant (Additional file 1:
Table S1). Although this encouraging result is from a
small number of elderly patients and a relatively short
observational period, we could insist that certain selection
criteria for TNF inhibitors in elderly RA patients are
reasonable in real-world clinical practice.
Our study includes certain limitations. First, the
current study includes a small number of elderly
patients. Further observational study using multiple
data sources is needed to evaluate long-term effective-
ness and safety for elderly RA patients. Second, we
Table 4 Incidence rates (95 % CI) of severe adverse events among RA patients
System organ class allocation Total (838 PYs) Elderly patients (212 PYs) Younger patients (626 PYs) IRR (elderly patient/younger patients)
Total 5.37 (3.92 – 7.19) 6.13 (3.27 – 10.49) 5.11 (3.50 – 7.22) 1.20 (0.63–2.29)
General disorders 0.12 (0.00 – 0.66) 0.47 (0.01 – 2.63) –
Hypersensitivity 0.24 (0.03 – 0.86) – 0.32 (0.04 – 1.15)
Hepatobiliary disorders 0.48 (0.13 – 1.22) 0.47 (0.01 – 2.63) 0.48 (0.10 – 1.40) 0.98 (0.10–9.46)
Infections 2.39 (1.46 – 3.69) 2.36 (0.77 – 5.50) 2.40 (1.34 – 3.95) 0.98 (0.36–2.71)
Injury 0.60 (0.19 – 1.39) 0.94 (0.11 – 3.41) 0.48 (0.10 – 1.40) 1.97 (0.33–11.78)
Musculoskeletal and connective
tissue disorders
0.24 (0.03 – 0.86) – 0.32 (0.04 – 1.15)
Malignant 0.95 (0.41 – 1.88) 0.94 (0.11 – 3.41) 0.96 (0.35 – 2.09) 0.98 (0.20–4.88)
Nervous system disorders 0.12 (0.00 – 0.66) 0.47 (0.01 – 2.36) –
Respiratory, thoracic, and
mediastinal disorders
0.24 (0.03 – 0.86) 0.47 (0.01 – 2.36) 0.16 (0.00 – 0.89) 2.95 (0.18–47.21)
CI confidence interval, RA rheumatoid arthritis, PYs patient–years, IRR incidence rate ratio. Values are Incidence per 100 PYs
Bold means statistical significant at the p < 0.05
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did not consider elderly onset patients because
patients were classified based on the age when they
started TNF inhibitors. Effectiveness and safety in
elderly onset patients may be different because their
disease characteristics are different. Elderly onset RA
is more often associated with joint erosions, higher
disease activity, and higher HAQ scores at baseline
[33]. However, initial aggressive treatment or multiple
combinations can be difficult to apply in elderly onset
RA patients. Therefore, the effectiveness and safety of
TNF inhibitors should be studied. Thirdly, we could
not evaluate retention rate and safety for each TNF
inhibitor because of our small population. Since so
many TNF inhibitors, including biosimilars and bio-
logic DMARDs with other mechanisms, are available
worldwide, further effort should invested in identify-
ing a strategy for appropriate selection of biologic
DMARDs for elderly RA patients.
Conclusions
The retention rate of TNF inhibitors in the elderly RA
group was comparable to that in the younger group. The
major cause of discontinuation in elderly patients was AE,
while the major cause of discontinuation in younger
patients was ineffectiveness. The IRs of injury and respira-
tory disorder in elderly patients were higher than those in
younger patients, but the differences were not statistically
significant.
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Additional file 1: Table S1. Incidence rates (95 % CI) of severe adverse
events among RA patients; subgroup analysis for more elderly patients ≥
65 years old. (DOCX 15 kb)
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